Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Organisation › Details

University of Texas System

	Start	2000-09-01 existent
	Industry	science

	Region	Texas (federal state)
	Country	United States (USA)
	City	n. a.
		Address record changed: 2011-05-15

Basic data	Employees	n. a.


		Record changed: 2018-10-31

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for University of Texas System

[1] CureVac N.V.. (7/3/24). "Press Release: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities". Tübingen & Boston, MA....
[2] Eisbach Bio GmbH. (5/6/24). "Press Release: Eisbach Bio Announces FDA Clearance of IND Application for EIS-12656, a First-in-Class Allosteric Inhibitor of ALC1". Martinsried....
[3] CureVac N.V.. (4/16/24). "Press Release: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines". Tübingen & Houston, TX....
[4] ImmunOs Therapeutics AG. (4/25/23). "Press Release: ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board". Schlieren & Gaithersburg, MD....
[5] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
[6] Valo Health LLC. (11/10/20). "Press Release: Valo Health Adds Award-Winning Neurobiologist Virginie Buggia-Prevot Ph.D. and Computational Scientist Andrea Rossi Ph.D.". Boston, MA....
[7] NBE Therapeutics AG. (10/26/20). "Press Release: NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors". Basel....
[8] Taysha Gene Therapies. (4/29/20). "Press Release: Taysha Gene Therapies Launches with $30 Million Seed Financing and Unrivaled Strategic Partnership with the UT Southwestern Gene Therapy Program". Dallas, TX....
[9] Artios Pharma Ltd.. (11/6/19). "Press Release: Artios Pharma, MD Anderson and ShangPharma Announce In-licensing Agreement for DNA Damage Response Inhibitor". Cambridge, New York, NY, Houston, TX & South San Franicsco, CA....
[10] Cellectis S.A.. (10/29/19). "Press Release: First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]